Report Conveys Value and Threats of Nanotechnology Research
|
By LabMedica International staff writers Posted on 04 Feb 2013 |
While scientists constantly increase their knowledge of biology and the surrounding world, all this newly gleaned information has the potential to advance healthcare, it is also possible that the same discoveries can also be used in ways that cause extensive havoc.
A new report assessed the potential for nanosized particles to break the blood-brain barrier (BBB), the closely-knit layers of cells that provide the brain with the highest level of protection in the human body. Some neuroscientists are modifying nanoparticles that can cross the BBB so as to deliver medicines in a targeted and controlled way directly to diseased regions of the brain.
A new article published January 17, 2013, in the journal Nanomedicine: Nanotechnology, Biology and Medicine, came about out of a US Federal Bureau of Investigation (FBI) workshop held at the University of Notre Dame (West Bend, IN, USA) in September 2012, tackles this complicated “dual-use” a feature of nanotechnology research.
“The rapid pace of breakthroughs in nanotechnology, biotechnology, and other fields, holds the promise of great improvements in areas such as medical diagnosis and treatment,” said Dr. Kathleen Eggleson, a research scientist in Notre Dame University’s Center for Nano Science and Technology and the author of the study. “But the risk of misuse of these breakthroughs rises along with the potential benefit. This is the essence of the ‘dual-use dilemma.’”
At the same time, the report noted, “nanoparticles designed to cross the BBB constitute a serious threat…in the context of combat.” For instance, it is hypothesized that aerosol delivery of some nanoengineered agent in “a crowded indoor space” could cause serious harm to many people at once. The difficulties presented by dual-use research was highlighted in 2012 when a debate exploded over the publication of findings that indicate how, with several modifications, the H5N1 influenza virus can be altered in a way that would enable it to be transmitted between mammalian populations.
After a self-imposed one-year moratorium on this research, several laboratories worldwide reported that they will resume the research in early 2013. The FBI is actively responding to these advances in the scientific community. “The law enforcement-security community is seeking to strengthen the existing dialogue with researchers,” stated William So, of the FBI’s Biological countermeasures unit. “Science flourishes because of the open and collaborative atmosphere for sharing and discussing ideas. The FBI believes this model can do the same for our two communities [… and] create effective safeguards for science and national interests.”
The scientists and engineers who conduct nanoscale research have the ability and responsibility to consider the public safety features of their research and to act to protect society when necessary, argued Dr. Eggleson. “The relationship between science and society is an uneasy one, but it is undeniable on the whole and not something any individual can opt out of in the name of progress for humanity’s benefit. Thought about dual-use, and action when appropriate, is inherent to socially responsible practice of nanobiomedical science.”
Related Links:
Notre Dame University’s Center for Nano Science and Technology
A new report assessed the potential for nanosized particles to break the blood-brain barrier (BBB), the closely-knit layers of cells that provide the brain with the highest level of protection in the human body. Some neuroscientists are modifying nanoparticles that can cross the BBB so as to deliver medicines in a targeted and controlled way directly to diseased regions of the brain.
A new article published January 17, 2013, in the journal Nanomedicine: Nanotechnology, Biology and Medicine, came about out of a US Federal Bureau of Investigation (FBI) workshop held at the University of Notre Dame (West Bend, IN, USA) in September 2012, tackles this complicated “dual-use” a feature of nanotechnology research.
“The rapid pace of breakthroughs in nanotechnology, biotechnology, and other fields, holds the promise of great improvements in areas such as medical diagnosis and treatment,” said Dr. Kathleen Eggleson, a research scientist in Notre Dame University’s Center for Nano Science and Technology and the author of the study. “But the risk of misuse of these breakthroughs rises along with the potential benefit. This is the essence of the ‘dual-use dilemma.’”
At the same time, the report noted, “nanoparticles designed to cross the BBB constitute a serious threat…in the context of combat.” For instance, it is hypothesized that aerosol delivery of some nanoengineered agent in “a crowded indoor space” could cause serious harm to many people at once. The difficulties presented by dual-use research was highlighted in 2012 when a debate exploded over the publication of findings that indicate how, with several modifications, the H5N1 influenza virus can be altered in a way that would enable it to be transmitted between mammalian populations.
After a self-imposed one-year moratorium on this research, several laboratories worldwide reported that they will resume the research in early 2013. The FBI is actively responding to these advances in the scientific community. “The law enforcement-security community is seeking to strengthen the existing dialogue with researchers,” stated William So, of the FBI’s Biological countermeasures unit. “Science flourishes because of the open and collaborative atmosphere for sharing and discussing ideas. The FBI believes this model can do the same for our two communities [… and] create effective safeguards for science and national interests.”
The scientists and engineers who conduct nanoscale research have the ability and responsibility to consider the public safety features of their research and to act to protect society when necessary, argued Dr. Eggleson. “The relationship between science and society is an uneasy one, but it is undeniable on the whole and not something any individual can opt out of in the name of progress for humanity’s benefit. Thought about dual-use, and action when appropriate, is inherent to socially responsible practice of nanobiomedical science.”
Related Links:
Notre Dame University’s Center for Nano Science and Technology
Latest BioResearch News
- Breakthrough Genetic Map Advances Understanding of Bone Disorders
- Study Identifies Hereditary Subtype of Aggressive Prostate Cancer
- Gene Variants Linked to Pollution-Exacerbated Asthma
- Single-Cell Analysis Mapping Links Inflammation Response to Acute Myeloid Leukemia
- Study Reveals New Insights into Rare Blood Cancer Development
- New Findings Clarify Molecular Drivers of Rare Small Intestinal Cancer
- Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
- Tumor Genome Marker May Predict Treatment Benefit in Pediatric Cancers
- Lysosomal Gene Defect Linked to Severe Childhood Brain Disorders
- Genetic Testing Identifies Greater Inherited Sudden Cardiac Arrest Risk in Younger Individuals
- Hidden 'Jumping Gene' Variant Linked to Higher Pancreatic Cancer Risk
- Common White Blood Cells Produce Schizophrenia-Linked Protein
- Nanopore Method Captures RNA Folding at Single-Molecule Resolution
- Tumor Microenvironment Marker Linked to Worse Survival in Solid Tumors
- Hidden Immune Gene Defect May Explain Kaposi Sarcoma Susceptibility
- Genetic Markers May Help Predict Amputation Risk in Peripheral Artery Disease
Channels
Clinical Chemistry
view channel
New Machine-Learning Equation Improves LDL Cholesterol Assessment
Accurate assessment of low-density lipoprotein (LDL) cholesterol is central to cardiovascular risk management, yet calculation methods can underestimate values in some patients. Laboratories widely use... Read more
Blood Biomarker May Signal Cognitive Decline Risk a Decade Before Symptoms
Accurately identifying which cognitively healthy older adults will later develop impairment due to Alzheimer’s disease remains difficult, as brain scans and genetic testing provide only part of the risk picture.... Read moreMolecular Diagnostics
view channel
HPV Assay Gains Expanded CE Mark for Self-Collected Vaginal Samples
Cervical cancer is the fourth most common cancer in women and is largely preventable through vaccination and regular screening. However, even where organized screening programs exist, participation varies... Read more
Fully Automated Test Advances Hepatitis D Diagnosis and Monitoring
Hepatitis D virus infection can accelerate progression to cirrhosis and liver cancer, making timely diagnosis and longitudinal monitoring essential. Because hepatitis D depends on co-infection or superinfection... Read more
Blood Test Achieves Improved Detection of Advanced Precancerous Colorectal Lesions
Colorectal cancer is the second-leading cause of cancer-related death in the United States, yet screening uptake remains suboptimal. More than 50 million eligible adults are not up to date with recommended... Read moreHematology
view channel
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read moreImmunology
view channel
Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more
Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read moreMicrobiology
view channel
Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance mechanisms to guide effective therapy. Delays in profiling gram-negative organisms, which are frequently associated... Read more
Bacterial Growth Assay Predicts COVID-19 Severity From Plasma
COVID-19 presents with a wide clinical spectrum, from mild illness to severe, life-threatening disease. Early differentiation between patients likely to remain mild and those at risk of severe progression... Read morePathology
view channel
Imaging Platform Maps Lipid Accumulations in Fabry Heart Tissue
Mapping the spatial distribution of disease-relevant molecules within tissue remains a diagnostic challenge, particularly before alterations are visible by conventional microscopy. In Fabry disease, a... Read more
AI Tissue Imaging Helps Guide Targeted Therapy for Lung Cancer
Lung cancer is the leading cause of cancer-related death, and many patients require rapid genotyping to guide targeted therapy selection. Current workflows often rely on molecular tests that are costly,... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Leica Biosystems to Expand Pathology Portfolio Through StatLab Acquisition
Leica Biosystems, an operating company of Danaher, has entered into a definitive agreement to acquire privately held StatLab Medical Products from Linden Capital Partners and Audax Private Equity.... Read more








